7/1/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Ruxience

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Rituximab

Rituximab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Ngu SF, Ngan HY. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33(0):86-101.

  2. Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017;29(5):328-334.

  3. Lambertini M, Peccatori FA, Azim HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015;41(4):301-9.

  4. Metcalfe A, Cairncross ZF, McMorris CA, Friedenreich CM, Nelson G, Bhatti P et al. Cancer chemotherapy in pregnancy and adverse pediatric outcomes: a population-based cohort study. J Natl Cancer Inst. 2025;117(3):554-561.

  5. Van Assche IA, Van Calsteren K, Huis In 't Veld EA, van Gerwen M, Heylen L, LeJeune CL et al. Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study. EClinicalMedicine. 2024;78:102922.

  6. Van Assche IA, Huis In 't Veld EA, Van Calsteren K, van Gerwen M, Blommaert J, Cardonick E et al. Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study. J Clin Oncol. 2023;41(8):1527-1532.

  7. Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance Centers et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101-10.

  8. TERIS (The Teratogen Information System). Use of methotrexate in pregnancy. August 2022. Version 21. UKTIS [www]. [cited 2025-04-16].

  9. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7(4):394-403.

  10. Haggar FA, Pereira G, Preen D, Holman CD, Einarsdottir K. Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. PLoS One. 2014;9(12):e113292.

  11. Dohle GR. Male infertility in cancer patients: Review of the literature. Int J Urol. 2010;17(4):327-31.

  12. Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL et al. Potential seminal transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58(0):213-21.

  13. Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol. 2005;74(2):119-31.

  14. De Cock D, Birmingham L, Watson KD, Kearsley-Fleet L, BSRBR Control Centre Consortium, Symmons DP et al. Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology (Oxford). 2017;56:661-663.

  15. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499-506.

  16. Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can Fam Physician 2007;53:409-12.

  17. Shah S, Eckstein C. B cell depletion and pregnancy: Review and applications for MS treatment. Mult Scler Relat Disord. 2019;33(0):153-157.

  18. Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):0.

  1. Ngu SF, Ngan HY. Chemotherapy in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016;33(0):86-101.
  2. Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017;29(5):328-334.
  3. Lambertini M, Peccatori FA, Azim HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev. 2015;41(4):301-9.
  4. Metcalfe A, Cairncross ZF, McMorris CA, Friedenreich CM, Nelson G, Bhatti P et al. Cancer chemotherapy in pregnancy and adverse pediatric outcomes: a population-based cohort study. J Natl Cancer Inst. 2025;117(3):554-561.
  5. Van Assche IA, Van Calsteren K, Huis In 't Veld EA, van Gerwen M, Heylen L, LeJeune CL et al. Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study. EClinicalMedicine. 2024;78:102922.
  6. Van Assche IA, Huis In 't Veld EA, Van Calsteren K, van Gerwen M, Blommaert J, Cardonick E et al. Cognitive and Behavioral Development of 9-Year-Old Children After Maternal Cancer During Pregnancy: A Prospective Multicenter Cohort Study. J Clin Oncol. 2023;41(8):1527-1532.
  7. Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Network of French Pharmacovigilance Centers et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101-10.
  8. TERIS (The Teratogen Information System). Use of methotrexate in pregnancy. August 2022. Version 21. UKTIS [www]. [cited 2025-04-16].
  9. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7(4):394-403.
  10. Haggar FA, Pereira G, Preen D, Holman CD, Einarsdottir K. Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. PLoS One. 2014;9(12):e113292.
  11. Dohle GR. Male infertility in cancer patients: Review of the literature. Int J Urol. 2010;17(4):327-31.
  12. Scialli AR, Bailey G, Beyer BK, Bøgh IB, Breslin WJ, Chen CL et al. Potential seminal transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58(0):213-21.
  13. Klemmt L, Scialli AR. The transport of chemicals in semen. Birth Defects Res B Dev Reprod Toxicol. 2005;74(2):119-31.
  14. De Cock D, Birmingham L, Watson KD, Kearsley-Fleet L, BSRBR Control Centre Consortium, Symmons DP et al. Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. Rheumatology (Oxford). 2017;56:661-663.
  15. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499-506.
  16. Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL. Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can Fam Physician 2007;53:409-12.
  17. Shah S, Eckstein C. B cell depletion and pregnancy: Review and applications for MS treatment. Mult Scler Relat Disord. 2019;33(0):153-157.
  18. Smith JB, Hellwig K, Fink K, Lyell DJ, Piehl F, Langer-Gould A. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):0.